130 results
Page 5 of 7
6-K
EX-99.1
yt36z roylic7o9xk
11 Aug 20
Management’s Discussion and Analysis of Financial Condition and Results of
12:00am
6-K
EX-99.2
xyb850qev2k6 82
11 Aug 20
Management’s Discussion and Analysis of Financial Condition and Results of
12:00am
6-K
EX-99.3
2df3b1b
3 Aug 20
Current report (foreign)
9:45pm
6-K
EX-99.2
ocnv5ojakdua
3 Aug 20
Current report (foreign)
9:45pm
SUPPL
uiuc u06jkdqsog
31 Jul 20
Supplemental materials (foreign)
9:43pm
6-K
EX-99.1
ij970v shtn6
13 Jul 20
Current report (foreign)
12:00am
SUPPL
j7lpo71z02vb20
13 Jul 20
Supplemental materials (foreign)
12:00am
F-10/A
EX-5.1
nzp3d81lbwkwmni
16 Jun 20
Registration of securities (Canada) (amended)
9:20pm
F-10/A
olcmlk7hg9ox535 71
16 Jun 20
Registration of securities (Canada) (amended)
9:20pm
F-10/A
EX-5.2
ss2hwieux ey
16 Jun 20
Registration of securities (Canada) (amended)
9:20pm
F-10/A
EX-7.1
zjz k3hpxysahgop9uz
16 Jun 20
Registration of securities (Canada) (amended)
9:20pm
6-K
EX-99.1
at5lu56b
16 Jun 20
Material Change Report
12:00am
6-K
EX-99.1
mng2oini7 8j
3 Jun 20
FSD Pharma Receives U.S. FDA Approval to design a Phase 2a Clinical Trial to Treat Patients with Suspected or Confirmed COVID-19 Diagnosis
10:41am
6-K
EX-99.1
mf2buaf
15 May 20
Management’s Discussion and Analysis of Financial Condition and Results of
10:48am
6-K
EX-99.2
u2bzx1aza 5ex
15 May 20
Management’s Discussion and Analysis of Financial Condition and Results of
10:48am
40-F/A
EX-99.10
9jjh9 145l1j7exj
17 Mar 20
Annual report (Canada) (amended)
5:14pm
40-F/A
EX-99.9
oad3 ie5ck39ulg2
17 Mar 20
Annual report (Canada) (amended)
5:14pm
40-F/A
EX-99.2
gero7ftpv48z4gres68
17 Mar 20
Annual report (Canada) (amended)
5:14pm
40-F
EX-99.9
w10lt434jdg 8jjxow1
4 Mar 20
Annual report (Canada)
12:29pm
40-F
EX-99.10
0eqggjgghse
4 Mar 20
Annual report (Canada)
12:29pm